glp-1 drugs alzheimer's Role of glucagon-like peptide-1 receptor agonists in disease and Parkinson's disease | Journal of Biomedical Science How GLP-1s Could Transform Alzheimer's

Ill leave that for another post

& Gossop, M

The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)

Semaglutide eligibility across all current indications for US adults

PlexusDx provides compounded versions from licensed 503A pharmacies, which may use slightly different excipients than brand-name formulations

My clinical experience, backed by research, shows that a patients weight can significantly influence their response to common RA treatments